Since YBX1 was already implicated in sorafenib resistance in HCC [62], also in the context of binding to circRNA-SORE [61], we also investigated the effect of sorafenib on the viability of our stable cell lines (Figure 7D and Figure S11). This evidence concerns the gene YBX1 and hepatocellular carcinoma.